Nexalin Technology Welcomes General Wesley Clark to Military & Government Advisory Board
Nexalin Technology (Nasdaq: NXL), specializing in Deep Intracranial Frequency Stimulation (DIFS™), has announced that General Wesley K. Clark, former NATO Supreme Allied Commander Europe, has joined its Military & Government Advisory Board. He will work alongside David F. Lasseter and William A. Hudson, Jr. to advance the company's neurostimulation solutions in military and government sectors.
The appointment supports Nexalin's ongoing 'Nexalin America' initiative, which focuses on addressing post-traumatic stress disorder, traumatic brain injury, and substance use disorder. The company's technology offers non-invasive, frequency-based, deep-brain stimulation devices aimed at treating various mental health conditions affecting service members and veterans.
Nexalin Technology (Nasdaq: NXL), specializzata in Stimolazione Frequenziale Intracranica Profonda (DIFS™), ha annunciato che il Generale Wesley K. Clark, ex Comandante Supremo delle Forze Alleate in Europa della NATO, si è unito al suo Consiglio Consultivo per il Settore Militare e Governativo. Lavorerà insieme a David F. Lasseter e William A. Hudson, Jr. per promuovere le soluzioni di neurostimolazione dell'azienda nei settori militare e governativo.
Questa nomina supporta l'iniziativa in corso 'Nexalin America' di Nexalin, che si concentra sull'affrontare il disturbo da stress post-traumatico, il trauma cranico e il disturbo da uso di sostanze. La tecnologia dell'azienda offre dispositivi di stimolazione cerebrale profonda, non invasivi e basati su frequenze, mirati a trattare varie condizioni di salute mentale che colpiscono i membri del servizio e i veterani.
Nexalin Technology (Nasdaq: NXL), especializada en Estimulación de Frecuencia Intracraneal Profunda (DIFS™), ha anunciado que el General Wesley K. Clark, ex Comandante Supremo de la OTAN en Europa, se ha unido a su Consejo Asesor Militar y Gubernamental. Trabajará junto a David F. Lasseter y William A. Hudson, Jr. para avanzar en las soluciones de neuroestimulación de la empresa en los sectores militar y gubernamental.
El nombramiento apoya la iniciativa 'Nexalin America' en curso de Nexalin, que se centra en abordar el trastorno de estrés postraumático, la lesión cerebral traumática y el trastorno por uso de sustancias. La tecnología de la empresa ofrece dispositivos de estimulación cerebral profunda, no invasivos y basados en frecuencias, destinados a tratar diversas condiciones de salud mental que afectan a los miembros del servicio y a los veteranos.
넥사린 테크놀로지 (Nasdaq: NXL)는 깊은 두개내 주파수 자극(DIFS™) 전문 기업으로, 웨슬리 K. 클락 장군이 NATO 유럽 최고 연합 사령관 출신으로 군 및 정부 자문 위원회에 합류했다고 발표했습니다. 그는 데이비드 F. 라세터 및 윌리엄 A. 허드슨 주니어와 함께 회사의 군 및 정부 부문에서의 신경 자극 솔루션을 발전시키기 위해 일할 것입니다.
이번 임명은 넥사린의 '넥사린 아메리카' 이니셔티브를 지원하며, 이는 외상 후 스트레스 장애, 외상성 뇌손상 및 물질 사용 장애를 다루는 데 중점을 두고 있습니다. 회사의 기술은 서비스 구성원과 재향 군인을 대상으로 다양한 정신 건강 문제를 치료하기 위해 설계된 비침습적이고 주파수 기반의 깊은 뇌 자극 장치를 제공합니다.
Nexalin Technology (Nasdaq: NXL), spécialisée dans la Stimulation Fréquentielle Intracrânienne Profonde (DIFS™), a annoncé que le Général Wesley K. Clark, ancien Commandant Suprême des Forces Alliées en Europe de l'OTAN, a rejoint son Conseil Consultatif Militaire et Gouvernemental. Il travaillera aux côtés de David F. Lasseter et William A. Hudson, Jr. pour faire avancer les solutions de neurostimulation de l'entreprise dans les secteurs militaire et gouvernemental.
Cette nomination soutient l'initiative en cours 'Nexalin America' de Nexalin, qui se concentre sur la prise en charge du trouble de stress post-traumatique, des blessures cérébrales traumatiques et des troubles liés à l'usage de substances. La technologie de l'entreprise propose des dispositifs de stimulation cérébrale profonde, non invasifs et basés sur des fréquences, visant à traiter diverses conditions de santé mentale touchant les membres du service et les vétérans.
Nexalin Technology (Nasdaq: NXL), spezialisiert auf tiefe intrakranielle Frequenzstimulation (DIFS™), hat bekannt gegeben, dass General Wesley K. Clark, ehemaliger NATO-Oberbefehlshaber in Europa, dem Militär- und Regierungsbeirat des Unternehmens beigetreten ist. Er wird zusammen mit David F. Lasseter und William A. Hudson, Jr. daran arbeiten, die Neurostimulationslösungen des Unternehmens in den militärischen und staatlichen Sektoren voranzutreiben.
Die Ernennung unterstützt die laufende Initiative 'Nexalin America' von Nexalin, die sich auf die Behandlung von posttraumatischen Belastungsstörungen, traumatischen Hirnverletzungen und Substanzmissbrauchsstörungen konzentriert. Die Technologie des Unternehmens bietet nicht-invasive, frequenzbasierte Geräte zur tiefen Hirnstimulation, die darauf abzielen, verschiedene psychische Gesundheitsprobleme bei Dienstmitgliedern und Veteranen zu behandeln.
- Strategic appointment of former NATO Supreme Commander strengthens government relations
- Enhanced potential for military and government contracts through advisory board expansion
- Targeting large market opportunity in veteran and military healthcare
- None.
HOUSTON, TX, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, is honored to announce that General Wesley K. Clark (Ret.), former NATO Supreme Allied Commander Europe, has joined its Military & Government Advisory Board. General Clark will collaborate with esteemed members David F. Lasseter, former Deputy Assistant Secretary of Defense for Policy, and William A. Hudson, Jr., former Acting General Counsel to the Department of Veterans Affairs, to advance Nexalin's innovative neurostimulation solutions within U.S. military and government sectors. The Company’s on-going “Nexalin America” initiative includes addressing post-traumatic stress disorder, traumatic brain injury, substance use disorder, and other areas of significant concern to the U.S. government.
General Clark's distinguished military career spans over three decades, during which he held numerous key positions, including NATO Supreme Allied Commander Europe. His extensive experience in strategic leadership and international affairs will be invaluable as Nexalin seeks to integrate its non-invasive, frequency-based, deep-brain stimulation devices into U.S. military healthcare initiatives.
Mark White, CEO of Nexalin Technology, stated, "We are privileged to welcome General Clark to our Advisory Board, supporting our Nexalin America initiative. His unparalleled leadership experience and deep understanding of military and governmental operations will be instrumental as we aim to provide drug-free, non-invasive treatments for mental health conditions affecting our service members and veterans."
General Clark commented, "I am honored to join Nexalin's Advisory Board and support the mission to deliver innovative mental health treatments. Addressing conditions such as PTSD, traumatic brain injury, anxiety, depression, and insomnia is critical for the well-being of our military personnel and veterans. Nexalin's technology offers promising solutions to these pressing challenges."
The Nexalin America program has already made significant contributions to Nexalin's initiatives within the government sector, and the addition of General Clark further strengthens the Advisory Board's collective expertise and commitment to improving mental health care for those who have served our nation.
Nexalin's Military & Government Advisory Board provides strategic advice and counsel to support the Company's advancement of its non-invasive, frequency-based, deep-brain stimulation devices in U.S. military and government agencies. The board's formation reflects Nexalin's dedication to fostering relationships within federal government and public sector organizations, including the U.S. Department of Defense, U.S. Department of Veterans Affairs, and U.S. Department of Health and Human Services.
About Nexalin Technology, Inc.
Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin’s products are non-invasive and undetectable to the human body and are developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper-penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15 milliamp neurostimulation device has been approved in China, Brazil, and Oman. Additional information about the Company is available at: https://nexalin.com/.
Forward-looking statements
This press release contains statements that constitute “forward-looking statements,” These statements relate to future events or Nexalin’s future financial performance. Any statements that refer to expectations, projections or other characterizations of future events or circumstances or that are not statements of historical fact (including without limitation statements to the effect that Nexalin or its management “believes”, “expects”, “anticipates”, “plans”, “intends” and similar expressions) should be considered forward-looking statements that involve risks and uncertainties which could cause actual events or Nexalin’s actual results to differ materially from those indicated by the forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's Report on Form 10-K for the year ended December 31, 2023, and other filings as filed with the Securities and Exchange Commission. Copies of such filings are available on the SEC’s website, www.sec.gov. Such forward-looking statements are made as of the date hereof and may become outdated over time. Such forward-looking statements are made as of the date hereof and may become outdated over time. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
Contact:
Crescendo Communications, LLC
Tel: (212) 671-1020
Email: NXL@crescendo-ir.com
FAQ
What is the purpose of Nexalin's Military & Government Advisory Board?
What medical conditions does Nexalin's technology target for military personnel?
Who are the current members of NXL's Military & Government Advisory Board?
What federal agencies is Nexalin (NXL) targeting for partnerships?
